The University of Southampton
University of Southampton Institutional Repository

ST1571 (Imatinib Mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response

ST1571 (Imatinib Mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response
ST1571 (Imatinib Mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response
The tyrosine kinase inhibitor STI571 (imatinib mesylate, Gleevec) is an effective treatment for chronic myeloid leukemia (CML). We examined bone marrow samples from 53 patients with CML who were receiving STI571 in 3 multicenter phase 2 trials to assess morphologic changes and cytogenetic response to this drug. In most patients with initially increased blasts, the bone marrow blast count rapidly decreased during STI571 therapy. Reductions in cellularity, the myeloid/erythroid ratio (commonly with relative erythroid hyperplasia), and reticulin fibrosis (if present pretreatment) also were seen in most patients, resulting in an appearance resembling normal marrow in many cases. Eighteen patients (34%) had some degree of cytogenetic response. Surprisingly, these striking morphologic changes occurred irrespective of any cytogenetic response to STI571. Thus, STI571 seems to affect the differentiation of CML cells in vivo, causing even extensively Philadelphia chromosome-positive hematopoiesis to exhibit features resembling normal hematopoiesis.
sti571, imatinib mesylate, gleevec, cml, therapy, pathology, bone marrow, cytogenetics
0002-9173
360-367
Hasserjian, Robert P.
0903b056-fcba-438e-bef2-9815b966b75c
Boecklin, Federica
f78cb47c-898b-402e-9ab4-bcae1af07858
Parker, Sally
6d99d938-18b6-4628-8c6b-91fcd0e3c1e6
Chase, Andy
a40a09c2-3073-4655-ba0b-a802e34914b5
Dhar, Sunanda
d9179ea3-fe6e-4d3b-9e39-2c6f7dcb3da8
Zaiac, M.
b8b5f7b5-a037-428a-964f-8a89d2c23eae
Olavarria, Eduardo
d612c401-581b-40c3-94d2-de0826de321b
Lampert, Irvin
61f0ff20-2340-47a0-907f-0b37eab413fe
Henry, Kristin
38703b9e-722a-4d04-9219-67eff321999b
Apperley, Jane F.
bb44333d-1437-4eb8-876a-37332e9ffcbc
Goldman, J. M.
2c27a1b3-c445-4593-a6b5-2e6e749fa1cb
Hasserjian, Robert P.
0903b056-fcba-438e-bef2-9815b966b75c
Boecklin, Federica
f78cb47c-898b-402e-9ab4-bcae1af07858
Parker, Sally
6d99d938-18b6-4628-8c6b-91fcd0e3c1e6
Chase, Andy
a40a09c2-3073-4655-ba0b-a802e34914b5
Dhar, Sunanda
d9179ea3-fe6e-4d3b-9e39-2c6f7dcb3da8
Zaiac, M.
b8b5f7b5-a037-428a-964f-8a89d2c23eae
Olavarria, Eduardo
d612c401-581b-40c3-94d2-de0826de321b
Lampert, Irvin
61f0ff20-2340-47a0-907f-0b37eab413fe
Henry, Kristin
38703b9e-722a-4d04-9219-67eff321999b
Apperley, Jane F.
bb44333d-1437-4eb8-876a-37332e9ffcbc
Goldman, J. M.
2c27a1b3-c445-4593-a6b5-2e6e749fa1cb

Hasserjian, Robert P., Boecklin, Federica, Parker, Sally, Chase, Andy, Dhar, Sunanda, Zaiac, M., Olavarria, Eduardo, Lampert, Irvin, Henry, Kristin, Apperley, Jane F. and Goldman, J. M. (2002) ST1571 (Imatinib Mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. American Journal of Clinical Pathology, 117 (3), 360-367.

Record type: Article

Abstract

The tyrosine kinase inhibitor STI571 (imatinib mesylate, Gleevec) is an effective treatment for chronic myeloid leukemia (CML). We examined bone marrow samples from 53 patients with CML who were receiving STI571 in 3 multicenter phase 2 trials to assess morphologic changes and cytogenetic response to this drug. In most patients with initially increased blasts, the bone marrow blast count rapidly decreased during STI571 therapy. Reductions in cellularity, the myeloid/erythroid ratio (commonly with relative erythroid hyperplasia), and reticulin fibrosis (if present pretreatment) also were seen in most patients, resulting in an appearance resembling normal marrow in many cases. Eighteen patients (34%) had some degree of cytogenetic response. Surprisingly, these striking morphologic changes occurred irrespective of any cytogenetic response to STI571. Thus, STI571 seems to affect the differentiation of CML cells in vivo, causing even extensively Philadelphia chromosome-positive hematopoiesis to exhibit features resembling normal hematopoiesis.

This record has no associated files available for download.

More information

Published date: 2002
Keywords: sti571, imatinib mesylate, gleevec, cml, therapy, pathology, bone marrow, cytogenetics

Identifiers

Local EPrints ID: 24741
URI: http://eprints.soton.ac.uk/id/eprint/24741
ISSN: 0002-9173
PURE UUID: fc7d37e7-2362-4a66-ab3a-a4bd4d490606
ORCID for Andy Chase: ORCID iD orcid.org/0000-0001-6617-9953

Catalogue record

Date deposited: 05 Apr 2006
Last modified: 08 Jan 2022 02:56

Export record

Contributors

Author: Robert P. Hasserjian
Author: Federica Boecklin
Author: Sally Parker
Author: Andy Chase ORCID iD
Author: Sunanda Dhar
Author: M. Zaiac
Author: Eduardo Olavarria
Author: Irvin Lampert
Author: Kristin Henry
Author: Jane F. Apperley
Author: J. M. Goldman

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×